Search

Your search keyword '"Palatka, Károly"' showing total 161 results

Search Constraints

Start Over You searched for: Author "Palatka, Károly" Remove constraint Author: "Palatka, Károly"
161 results on '"Palatka, Károly"'

Search Results

1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

3. A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése

4. A Crohn-betegég terápiás stratégiája

6. Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.

8. Chronic Inflammatory Intestinal Disorders in Hidradenitis Suppurativa

11. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease

12. Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis

13. Mannose-binding lectin level and deficiency is not associated with inflammatory bowel diseases, disease phenotype, serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort

15. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

16. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

18. Combination therapy with anti-TNFs and thiopurines does affect drug metabolite levels but it is not associated with body composition in inflammatory bowel disease patients: A cross-sectional study

20. IBD-related malignancies observed in 2015-2018: 4 years' results from the prospective nationwide Hungarian registry

23. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

24. Endoscopic sphincterotoMy for delayIng choLecystectomy in mild acute biliarY pancreatitis (EMILY study): protocol of a multicentre randomised clinical trial

26. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

27. IBD-related malignancies and mortalities observed in 2015-2017: 3 years' results from the prospective nationwide Hungarian registry

30. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.

31. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort

32. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease

36. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

38. What Is the Personal Experience of IBD Patients about Their Anti-TNF-Alpha Therapy?

39. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

40. Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn’s disease—A multicenter “real life” study

41. Az adalimumab hatékonysága és biztonságossága hagyományos kezelésre refrakter colitis ulcerosában

42. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis

43. Hepatitis C-vírussal fertôzött cirrhosisos betegek kezelésével nyert hazai real-life tapasztalatok a két pegilált interferonnal

45. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

49. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

50. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

Catalog

Books, media, physical & digital resources